Delix Therapeutics, a private company building drugs it calls neuroplastogens, announced on November 9 that it had closed an oversubscribed $100 million Series C. Johnson & Johnson’s venture arm, JJDC, co-led the round with SV Health Investors’ Dementia Discovery Fund, and representatives of both joined Delix’s board.

By Delix’s account, the money pays for the test that matters. Its lead drug, zalsupindole, is meant to deliver the antidepressant benefit associated with psychedelics as an oral pill taken at home, without hallucinations. So far the case for that rests on a small study in which every patient received the drug. The Series C is meant to fund a placebo-controlled test of whether it works.

What the round buys

Delix says the financing will carry zalsupindole “through Phase IIb Proof of Concept in recurrent Major Depressive Disorder,” fund additional development candidates and expand a neurodegeneration program it describes as having preclinical efficacy signals. It expects the Phase II trial to begin in the first half of 2027.

The design was already settled. On October 28, 2025, Delix announced that FDA had cleared its investigational new drug application for a multi-site, randomized, double-blind, placebo-controlled Phase II with three arms (placebo, once-daily dosing and twice-weekly dosing), an adaptive interim analysis, and self-administration at home. A year later the trial has not started.

Several things Delix has not disclosed:

  • the Phase II’s size, primary endpoint, duration, geography or expected readout date, or whether the “Phase IIb” in its funding statement is the Phase II FDA cleared (ClinicalTrials.gov, searched November 10, lists no zalsupindole study, the Phase Ib included);
  • how much JJDC or any other investor contributed, the valuation, and whether the $100 million includes converted notes;
  • how long the cash lasts. The chief executive says the capital takes zalsupindole “through Phase II Proof of Concept,” which is the company’s own funding claim, not a disclosed runway.

Before this round, Delix announced a $70 million Series A in 2021 and $30 million in convertible notes in January 2022.

The evidence behind “take-home”

Delix describes zalsupindole as an orally available neuroplastogen inspired by 5-MeO-DMT, the psychedelic also known as mebufotenin, and engineered to promote neuroplasticity without hallucinatory, dissociative or sedative effects.

Its only efficacy data come from a Phase Ib study in 18 adults with major depressive disorder. According to Delix’s October 2025 release:

  • Primary objective: effects on brain-activity and sleep biomarkers (quantitative EEG and polysomnography). Efficacy was a secondary, preliminary objective.
  • Dosing: all 18 received zalsupindole. One cohort took it once daily for seven days; the other took it twice in the first week. Cohort sizes, baseline scores and measures of spread were not given.
  • Result: depression scores on the Montgomery-Åsberg scale (MADRS) fell by about 12 points, roughly 50 percent, at Day 8, the first measurement, in both cohorts. The improvement held through Day 36, four weeks after the last dose.
  • Safety: no serious adverse events; all adverse events were mild and resolved without intervention.
  • Comparator: none is described. Delix called it “the first clinical trial exploring efficacy” for the compound.

That is a change from baseline in 18 people, not a treatment effect. Without a comparison group, the study cannot separate the drug’s contribution from placebo response or the natural course of depression. The equal response to seven doses and to two is interesting, but with no placebo arm it cannot show which regimen works or whether either does. The Phase II’s three-arm design exists to answer those questions.

The safety claim is broader but has the same limit. Delix says that in more than 120 participants studied to date, no hallucinatory, dissociative or psychotomimetic effects were seen on clinician-administered scales, patient-reported scales or objective measures. That count was already “over 120” in October 2025, so the Series C release adds no new human data. Neither release says how many of those participants received the drug, at what doses, or how many were healthy volunteers rather than patients with depression; the October 2025 release refers to earlier Phase I data in healthy volunteers. A sample of that size can show the drug is not a conventional psychedelic at the doses tested. It cannot rule out rarer risks in the larger, sicker population a take-home antidepressant would reach.

What “at-home” does and does not mean

The at-home model is the commercial thesis. Delix contrasts zalsupindole with traditional psychedelics, which it says “will be limited to in-clinic care, later-line therapies, and infrequent administration.”

FDA’s 2025 action allowed patients in a trial to take the drug at home. It was not a decision about how an approved product would be labeled, monitored or restricted, and Delix’s description of the clearance as “validating the compound’s safety” goes further than an IND clearance does. Neither release says whether Delix has discussed with FDA what monitoring, if any, an approved drug would need.

JJDC is an investor, not a partner

JJDC is J&J’s corporate venture capital arm. The Series C release discloses no license, option, right of first refusal, collaboration or other commercial right for J&J, and quotes no one from J&J. Its board representative is unnamed. J&J’s own depression franchise includes SPRAVATO, an esketamine nasal spray given in certified healthcare settings with monitoring after each dose. A venture stake does not say how J&J views the two models, and it is not a sign that J&J intends to acquire or license Delix.

What the round does establish is narrower. Investors that include a large pharmaceutical company’s venture arm put money behind a plan to test the at-home, non-hallucinogenic idea against placebo, on terms Delix has not disclosed. Whether the effect seen in 18 people survives a placebo arm is what the Phase II will show, and Delix has not said when that answer arrives.